Drugs / PTG-CARCIK-CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05252403 | Dec 2021 → Dec 2024 | acute lymphoblastic leukemia | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTG-CARCIK-CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252403 ↗ |
| Modality | Cell therapy | “genetically modified allogeneic T lymphocytes” NCT05252403 ↗ |